SMMT logo

SMMT
Summit Therapeutics Inc

9,551
Mkt Cap
$13.27B
Volume
1.39M
52W High
$36.91
52W Low
$15.55
PE Ratio
-14.41
SMMT Fundamentals
Price
$17.83
Prev Close
$17.82
Open
$18.02
50D MA
$19.47
Beta
1.18
Avg. Volume
3.59M
EPS (Annual)
-$0.308
P/B
69.27
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Hold" by Analysts
Shares of Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report) have received a consensus recommendation of "Hold" from the nineteen analysts that are currently covering the stock, MarketBeat.com...
MarketBeat·2d ago
News Placeholder
Police & Firemen s Retirement System of New Jersey Purchases 24,163 Shares of Summit Therapeutics PLC $SMMT
Police & Firemen s Retirement System of New Jersey raised its position in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 118.3% in the second quarter, according to the company in its most...
MarketBeat·5d ago
News Placeholder
40,169 Shares in Summit Therapeutics PLC $SMMT Acquired by Neo Ivy Capital Management
Neo Ivy Capital Management bought a new stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the...
MarketBeat·6d ago
News Placeholder
Catalyst Funds Management Pty Ltd Purchases New Position in Summit Therapeutics PLC $SMMT
Catalyst Funds Management Pty Ltd purchased a new position in shares of Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) during the second quarter, according to the company in its most recent...
MarketBeat·8d ago
News Placeholder
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Wolfe Research
Wolfe Research began coverage on shares of Summit Therapeutics in a research note on Tuesday. They issued a "peer perform" rating on the stock...
MarketBeat·10d ago
News Placeholder
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Zacks·12d ago
News Placeholder
Candriam S.C.A. Sells 324,755 Shares of Summit Therapeutics PLC $SMMT
Candriam S.C.A. decreased its holdings in shares of Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 38.7% in the 2nd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·13d ago
News Placeholder
Fiera Capital Corp Takes $16.66 Million Position in Summit Therapeutics PLC $SMMT
Fiera Capital Corp acquired a new position in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·14d ago
News Placeholder
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
Zacks·19d ago

Latest SMMT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.